Personalized mRNA Vaccine Cuts Melanoma Recurrence Risk by Over 40 Percent
A new personalized mRNA vaccine has demonstrated a significant breakthrough in clinical trials, reducing the risk of melanoma recurrence or death by over 40 percent. By tailoring the vaccine to individual tumor mutations, this Phase 3 trial success highlights the expanding potential of mRNA technology beyond infectious diseases to revolutionize cancer immunotherapy and patient outcomes.
Source: Wired